2 High-Yield Healthcare Stocks to Buy Before They Raise Payouts

AbbVie offers a 3.3% dividend yield with a $1.73 quarterly payout, while Medtronic yields 3.7% and just delivered its 48th consecutive annual dividend increase. The article argues both healthcare names have durable cash flow and strong dividend growth potential, with AbbVie already a Dividend King and Medtronic nearing that status. This is a constructive dividend-focused piece rather than a catalyst-driven market event.

Analysis

The market is likely underappreciating how much of AbbVie’s equity story has already shifted from single-product risk to cash-flow compounding. That matters because once a “patent cliff” narrative is disarmed, the stock tends to re-rate less on growth and more on capital return durability; that usually compresses volatility and supports multiple expansion versus other large-cap pharma names still fighting exclusivity overhangs. The second-order effect is that AbbVie’s steady dividend growth can become a cheap long-duration bond proxy for income allocators, crowding out lower-quality high yield equities.

Medtronic’s setup is different: the key isn’t yield alone, it’s the combination of slow but dependable free cash flow with an aging-population tailwind that is unusually visible over a 3-5 year horizon. If procedure volumes normalize and hospital capex budgets improve, incremental margin on a $33B+ revenue base can flow through faster than consensus expects, especially because mature medtech names often benefit from operating leverage when pricing pressure stabilizes. That creates a subtle relative-value opportunity versus slower-growth healthcare services or device peers with less balance-sheet flexibility.

The consensus is probably too focused on dividend labels and not enough on payout sustainability versus reinvestment optionality. The real risk to both names is not near-term earnings, but a regime shift where rates stay higher for longer and equity income investors start demanding wider spreads for dividend growth visibility; in that world, these names can still work, but the multiple ceiling is lower. For AbbVie, the catalyst is continued execution that proves the post-Humira earnings base is more durable than feared; for Medtronic, it is evidence that growth can re-accelerate modestly without margin dilution.

Key Decisions for Investors

• Long ABBV on a 3-6 month horizon as a defensive income compounder; target a low-double-digit total return if dividend support and multiple stabilization persist, with risk centered on pipeline disappointment or any sign the post-Humira cash engine is less resilient than assumed.
• Long MDT versus a basket of lower-quality dividend healthcare names over 6-12 months; the risk/reward favors a gradual rerating if free cash flow remains consistently above ~$5B and procedure volumes continue normalizing.